company background image
PTN logo

Palatin Technologies NYSEAM:PTN Stock Report

Last Price

US$1.87

Market Cap

US$25.8m

7D

15.4%

1Y

-32.0%

Updated

28 Mar, 2024

Data

Company Financials +

Palatin Technologies, Inc.

NYSEAM:PTN Stock Report

Market Cap: US$25.8m

PTN Stock Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

PTN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Palatin Technologies, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Palatin Technologies
Historical stock prices
Current Share PriceUS$1.87
52 Week HighUS$5.65
52 Week LowUS$1.43
Beta0.94
1 Month Change-52.90%
3 Month Change-53.02%
1 Year Change-32.00%
3 Year Change-89.54%
5 Year Change-92.81%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Shareholder Returns

PTNUS BiotechsUS Market
7D15.4%0.9%0.4%
1Y-32.0%10.3%28.8%

Return vs Industry: PTN underperformed the US Biotechs industry which returned 10.3% over the past year.

Return vs Market: PTN underperformed the US Market which returned 28.8% over the past year.

Price Volatility

Is PTN's price volatile compared to industry and market?
PTN volatility
PTN Average Weekly Movement23.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PTN's share price has been volatile over the past 3 months.

Volatility Over Time: PTN's weekly volatility has increased from 16% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198634Carl Spanahttps://palatin.com

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.

Palatin Technologies, Inc. Fundamentals Summary

How do Palatin Technologies's earnings and revenue compare to its market cap?
PTN fundamental statistics
Market capUS$25.82m
Earnings (TTM)-US$35.04m
Revenue (TTM)US$7.10m

4.3x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PTN income statement (TTM)
RevenueUS$7.10m
Cost of RevenueUS$23.14m
Gross Profit-US$16.04m
Other ExpensesUS$19.01m
Earnings-US$35.04m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.17
Gross Margin-225.96%
Net Profit Margin-493.74%
Debt/Equity Ratio0%

How did PTN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.